LOCALLY ADVANCED RECTAL ADENOCARCINOMA
Clinical trials for LOCALLY ADVANCED RECTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED RECTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy cocktail shows promise against tough rectal cancers
Disease control CompletedThis study tested whether giving a mix of immunotherapy drugs (tislelizumab and IL-2) plus chemotherapy before surgery could shrink tumors more effectively in people with locally advanced rectal cancer. The trial involved 130 adults whose cancers had not spread but were hard to t…
Matched conditions: LOCALLY ADVANCED RECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Immunotherapy combo shows promise against tough rectal cancers
Disease control CompletedThis study tested whether adding an immunotherapy drug called APX005M to standard treatment helps people with advanced rectal cancer achieve a complete response (no cancer left after treatment). 58 adults with stage II or III rectal cancer at high risk took part. The goal was to …
Matched conditions: LOCALLY ADVANCED RECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy aims to shrink rectal tumors and save sphincters
Disease control CompletedThis phase 2 trial tested whether adding a PD-1 inhibitor (Sintilimab) after standard chemoradiotherapy could improve outcomes for 30 patients with locally advanced mid-low rectal cancer. Participants received radiation and chemotherapy, then three doses of Sintilimab, followed b…
Matched conditions: LOCALLY ADVANCED RECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC